Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

rFSH and HMG are both used to controlled ovarian stimulation for patients submitted to IVF. However, there is a debate in the literature which one is better to induce ovulation in patients receiving GnRH antagonist to block premature Luteinizing Hormone (LH) secretion.

The investigators propose a Randomized Clinical Trial (RCT) to investigate the differences among recombinant FSH and HMG in patients submitted to IVF using GnRH antagonists.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre
• Collaborator: Center for Human Reproduction
• Treatments: Follicle Stimulating Hormone; Hormones; Menotropins

Criteria

Inclusion Criteria:

• 25 to 40 y

• infertile

• submitted to IVF

• no hormonal disease

• normal FSH (< 10)

• anti-mullerian hormone (AMH) > 1 ng and < 10 ng

• both ovaries

• only first or second IVF

Exclusion Criteria:

• thyroid-stimulating hormone (TSH), prolactin (PRL) altered

• endometrioma

• ovarian tumor or cysts

• previous Ovarian Hyperstimulation Syndrome (OHSS)

• severe male factor